Related references
Note: Only part of the references are listed.The Global Ascendency of OXA-48-Type Carbapenemases
Johann D. D. Pitout et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
Elias M. Mullane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope
Lindsay M. Avery et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa
Bartolome Moya et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016
Dee Shortridge et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres
Zeb Khan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Patrice Nordmann et al.
CLINICAL INFECTIOUS DISEASES (2019)
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
Safa S. Almarzoky Abuhussain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Lindsay M. Avery et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Current Status and Trends of Antibacterial Resistance in China
Fupin Hu et al.
CLINICAL INFECTIOUS DISEASES (2018)
Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016
Irene Galani et al.
EUROSURVEILLANCE (2018)
Phenotypic and Genotypic Characterization of Enterobacteriaceae Producing Oxacillinase-48-Like Carbapenemases, United States
Joseph D. Lutgring et al.
EMERGING INFECTIOUS DISEASES (2018)
Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study
Spyros Pournaras et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
Matthew E. Falagas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
Helio S. Soder et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
Latania K. Logan et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods
Chang-Ro Lee et al.
FRONTIERS IN MICROBIOLOGY (2016)
Multi-drug carbapenem-resistant Klebsiella pneumoniae infection carrying the OXA-48 gene and showing variations in outer membrane protein 36 causing an outbreak in a tertiary care hospital in Riyadh, Saudi Arabia
Taher uz Zaman et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2014)
Global Spread of Carbapenemase-producing Enterobacteriaceae
Patrice Nordmann et al.
EMERGING INFECTIOUS DISEASES (2011)
Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin
K. Kontopoulou et al.
JOURNAL OF HOSPITAL INFECTION (2010)
First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests
Athanassios Tsakris et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of blaACT-1 β-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE
Frank M. Kaczmarek et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Simple microdilution test for detection of metallo-β-lactamase production in Pseudomonas aeruginosa
R Migliavacca et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Share Paper
